Design, synthesis, and biological evaluation of aminothiazole derivatives against the fungal pathogens Histoplasma capsulatum and Cryptococcus neoformans
摘要:
Invasive fungal disease constitutes a growing health burden and development of novel antifungal drugs with high potency and selectivity against new fungal molecular targets are urgently needed. Previously, an aminothiazole derivative, designated as 41F5, was identified in our laboratories as highly active against Histoplasma yeast (MIC50 0.4-0.8 mu M) through phenotypic high-throughput screening of a commercial library of 3600 purine mimicking compounds (Antimicrob. Agents Chemother. 2013, 57, 4349). Consequently, 68 analogues of 41F5 were designed and synthesized or obtained from commercial sources and their MIC(50)s of growth inhibition were evaluated in Histoplasma capsulatum to establish a basic structure-activity-relationship (SAR) for this potentially new class of antifungals. The growth inhibiting potentials of smaller subsets of this library were also evaluated in Cryptococcus neoformans and human hepatocyte HepG2 cells, the latter to obtain selectivity indices (SIs). The results indicate that a thiazole core structure with a naphth-1-ylmethyl group at the 5-position and cyclohexylamide-, cyclohexylmethylamide-, or cyclohexylethylamide substituents at the 2-position caused the highest growth inhibition of Histoplasma yeast with MIC(50)s of 0.4 mu M. For these analogues, SIs of 92 to > 100 indicated generally low host toxicity. Substitution at the 3- and 4-position decreased antifungal activity. Similarities and differences were observed between Histoplasma and Cryptococcus SARs. For Cryptococcus, the naphth-1-ylmethyl substituent at the 5-position and smaller cyclopentylamide- or cyclohexylamide groups at the 2-position were important for activity. In contrast, slightly larger cyclohexylmethyl- and cyclohexylethyl substituents markedly decreased activity. (C) 2014 Elsevier Ltd. All rights reserved.
Discovery and Potency Optimization of 2-Amino-5-arylmethyl-1,3-thiazole Derivatives as Potential Therapeutic Agents for Prostate Cancer
作者:Mikhail Krasavin、Ruben Karapetian、Igor Konstantinov、Yuri Gezentsvey、Konstantin Bukhryakov、Elena Godovykh、Olga Soldatkina、Yan Lavrovsky、Andrei V. Sosnov、Andrei A. Gakh
DOI:10.1002/ardp.200800201
日期:2009.7
antiproliferative activity on DU‐145 human prostate carcinoma cell line (hit compound potency – 2.9 μM). Medicinal chemistry optimization of two peripheral diversity vectors of the hit molecule, independently, led to SAR generalizations and identification of the ‘best’ moieties. The latter were merged in a single compound that exhibited an over 100‐fold better potency than the hit compound. For the most potent
通过高通量筛选确定了一个新的化学系列,它对 DU-145 人前列腺癌细胞系具有抗增殖活性(命中化合物效力 - 2.9 μM)。对命中分子的两个外围多样性载体的药物化学优化,独立地导致 SAR 概括和“最佳”部分的鉴定。后者合并为单一化合物,其效力比命中化合物高 100 倍以上。对于最有效的化合物,已证实观察到的抗增殖效力与化合物的非特异性细胞毒性无关。